Syros Pharmaceuticals Inc. (SYRS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
LSE 
Syros Pharmaceuticals, Inc. (SYRS) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.
An Investigation Has Commenced on Behalf of Syros Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SYRS Losses.
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.
Investors who lost money on Syros Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - SYRS
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.
ATTENTION SYRS SHAREHOLDERS: Investors who lost money on Syros Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / August 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.
SYRS ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Syros Pharmaceuticals, Inc.
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Syros Pharmaceuticals, Inc. ("Syros Pharmaceuticals") (NASDAQ:SYRS) concerning possible violations of federal securities laws. Syros issued a press release on August 12, 2024, "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ:SYRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.
Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Syros Pharmaceuticals (SYRS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today?
Syros Pharmaceuticals (NASDAQ: SYRS ) stock is falling hard on Tuesday after the biopharmaceutical company provided an update on a Phase 2 clinical trial. Syros Pharmaceuticals has announced that it is discontinuing enrollment in its SELECT-AML-1 Phase 2 clinical trial.
Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 251.9% in Syros Pharmaceuticals (SYRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Syros Pharmaceuticals, Inc. (SYRS) Q2 2024 Earnings Call Transcript
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS ) Q2 2024 Earnings Conference Call July 31, 2024 8:30 AM ET Company Participants Karen Hunady - Director of Investor Relations and Corporate Communications Conley Chee - President and Chief Executive Officer David Roth - Chief Medical Officer Jason Haas - Chief Financial Officer Conference Call Participants Philip Nadeau - TD Cowen Ted Tenthoff - Piper Sandler Roy Buchanan - Citizens JMP Leah Cann - Brookline Capital Markets Operator Good morning, and welcome to Syros Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, which is being studied for two different cancer indications.
